These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9476376)

  • 41. Pamidronate infusions for the treatment of Paget's disease of bone.
    Mazieres B; Ahmed I; Moulinier L; Bon E; Cantagrel A; Laroche M
    Rev Rhum Engl Ed; 1996 Jan; 63(1):36-43. PubMed ID: 9064108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
    Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B
    Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Paget's disease: case report].
    Wegierska M; Ignaczak P; Zalewska J; Jeka S
    Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response of biochemical markers of bone turnover to pamidronate infusion in Paget's disease of bone.
    Sharp CA; Worsfold M; Rowlands PR; Davie MW
    Semin Arthritis Rheum; 1994 Feb; 23(4):242-3. PubMed ID: 8009239
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of Paget's disease with olpadronate. Its efficacy in partial responders to oral pamidronate].
    González D; Pastrana M; Mautalen C
    Medicina (B Aires); 1997; 57 Suppl 1():25-31. PubMed ID: 9567351
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paget's disease of bone: presentation, extent and response to bisphosphonates.
    Wang LM; Au-Yeong ML; McKenna MJ
    Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Determinants of remission of Paget's disease of bone.
    Patel S; Stone MD; Coupland C; Hosking DJ
    J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term efficacy of intravenous pamidronate in Paget's disease of bone.
    Grauer A; Klar B; Scharla SH; Zieglar R
    Semin Arthritis Rheum; 1994 Feb; 23(4):283-4. PubMed ID: 8009261
    [No Abstract]   [Full Text] [Related]  

  • 51. Measurement of bone mineral density by dual X-ray absorptiometry in Paget's disease before and after pamidronate treatment.
    Laroche M; Delpech B; Bernard J; Constantin A; Mazières B
    Calcif Tissue Int; 1999 Sep; 65(3):188-91. PubMed ID: 10441648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone.
    Ryan PJ; Gibson T; Fogelman I
    J Nucl Med; 1992 Sep; 33(9):1589-93. PubMed ID: 1517830
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease--a controlled pilot study.
    Bender T; Donáth J; Barna I; Gergely P; Poór G
    Neuro Endocrinol Lett; 2006 Aug; 27(4):513-5. PubMed ID: 16891991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of the bisphosphonate APD in the control of Paget's bone disease.
    Mautalen CA; Gonzalez D; Ghiringhelli G
    Bone; 1985; 6(6):429-32. PubMed ID: 4096879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.
    Reid IR; Davidson JS; Wattie D; Wu F; Lucas J; Gamble GD; Rutland MD; Cundy T
    Bone; 2004 Jul; 35(1):224-30. PubMed ID: 15207761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paget's disease of bone.
    Tran HA
    Med J Aust; 2005 Feb; 182(3):138-9. PubMed ID: 15698363
    [No Abstract]   [Full Text] [Related]  

  • 58. Single-day intravenous pamidronate in Paget's disease.
    Hooper MJ; Clifton-Bligh P; Marel GM; Lang FV; Tancred J; McDowall D; Forman L
    Semin Arthritis Rheum; 1994 Feb; 23(4):276-7. PubMed ID: 8009255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Updates on Paget's Disease of Bone.
    Choi YJ; Sohn YB; Chung YS
    Endocrinol Metab (Seoul); 2022 Oct; 37(5):732-743. PubMed ID: 36327984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.